TNFRSF8 and Hodgkins lymphoma: In the last decade, therapeutic strategies for the management of Hodgkin lymphoma have undergone major changes that are primarily associated with the addition of the anti-CD30 antibody drug conjugate and checkpoint inhibitors to the first-line chemotherapy.